Lung Cancer

Multidisciplinary Tumor Board: Focus on Early-Stage KRAS Mutated NSCLC

Brendon Stiles, MD; Charu Aggarwal, MD, MPH
Management of Borderline Resectable NSCLC

Gavitt Woodardi, MD; Charu Aggarwal, MD, MPH
NSCLC: The Evolving Landscape of KRAS G12C Therapy

Timothy F. Burns, MD, PhD; Charu Aggarwal, MD, MPH
Management of Borderline Resectable NSCLC

Aditya Juloori, MD; Charu Aggarwal, MD, MPH
Multidisciplinary Lung Cancer Tumor Board: Focus on Oligometastatic NSCLC

Puneeth Iyengar, MD, PhD; Charu Aggarwal, MD, MPH
The Evolving Roles of Neoadjuvant and Adjuvant Therapy in EGFRm NSCLC

Tina Cascone, MD, PhD
Updates in Small Cell Lung Cancer

Jacob Sands, MD
Importance of NGS testing for STK11 and KEAP1 mutation and impact on treatment selection

Charu Aggarwal, MD, MPH, Biagio Ricciuti, MD, PhD
Early Stage NSCLC – EGFR Mutant NSCLC

Charu Aggarwal, MD, MPH
Advances in The Management of Early-Stage EGFRm NSCLC

Charu Aggarwal, MD, MPH
The Evolving Approach to Management of Stage IV EGFRm NSCLC

Charu Aggarwal, MD, MPH
Advances in the Treatment of Small-Cell Lung Cancer

David R. Spigel, MD, FASCO